
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.
Susan F. Slovin, MD, PhD, medical oncologist, associate vice chair, Academic Administration, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses emergence of 177Lu-PSMA-617 (LuPSMA) and overall significance of radiopharmaceuticals inmetastatic castration-resistant prostate cancer (mCRPC)
Data from the






